Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;132(5):291-316.
doi: 10.1111/apm.13389. Epub 2024 Mar 11.

Antifungal drug resistance in Candida: a special emphasis on amphotericin B

Lailema Ahmady #  1 , Manisha Gothwal #  1 , Muhammed Mushthaque Mukkoli #  1 , Vinay Kumar Bari  1
Affiliations
Review

Antifungal drug resistance in Candida: a special emphasis on amphotericin B

Lailema Ahmady et al. APMIS. 2024 May.

Abstract

Invasive fungal infections in humans caused by several Candida species, increased considerably in immunocompromised or critically ill patients, resulting in substantial morbidity and mortality. Candida albicans is the most prevalent species, although the frequency of these organisms varies greatly according to geographic region. Infections with C. albicans and non-albicans Candida species have become more common, especially in the past 20 years, as a result of aging, immunosuppressive medication use, endocrine disorders, malnourishment, extended use of medical equipment, and an increase in immunogenic diseases. Despite C. albicans being the species most frequently associated with human infections, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei also have been identified. Several antifungal drugs with different modes of action are approved for use in clinical settings to treat fungal infections. However, due to the common eukaryotic structure of humans and fungi, only a limited number of antifungal drugs are available for therapeutic use. Furthermore, drug resistance in Candida species has emerged as a result of the growing use of currently available antifungal drugs against fungal infections. Amphotericin B (AmB), a polyene class of antifungal drugs, is mainly used for the treatment of serious systemic fungal infections. AmB interacts with fungal plasma membrane ergosterol, triggering cellular ion leakage via pore formation, or extracting the ergosterol from the plasma membrane inducing cellular death. AmB resistance is primarily caused by changes in the content or structure of ergosterol. This review summarizes the antifungal drug resistance exhibited by Candida species, with a special focus on AmB.

Keywords: Candida species; Candidiasis; amphotericin B; antifungal drug resistance; ergosterol.

PubMed Disclaimer

References

    1. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 2003;11(1):30–36. https://doi.org/10.1016/S0966-842X(02)00002-1
    1. Petri MG, König J, Moecke HP, Gramm HJ, Barkow H, Kujath P, et al. Epidemiology of invasive mycosis in ICU patients: A prospective multicenter study in 435 non‐neutropenic patients. Intensive Care Med. 1997;23(3):317–325. https://doi.org/10.1007/s001340050334
    1. Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU‐acquired candidemia in India. Intensive Care Med. 2015;41(2):285–295. https://doi.org/10.1007/s00134-014-3603-2
    1. Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care. 2011;1:37. https://doi.org/10.1186/2110-5820-1-37
    1. Hani U, Shivakumar H, Vaghela R, Osmani M, Shrivastava A. Candidiasis: A fungal infection‐current challenges and progress in prevention and treatment. Infect Disord Drug Targets. 2015;15(1):42–52. https://doi.org/10.2174/1871526515666150320162036

LinkOut - more resources